The multifactorial impact of receiving a hereditary angioedema diagnosis.

"Declaration of competing interests/disclosures JR reports receiving fees for serving as a consultant at advisory boards for CSL Behring, Octapharma USA, Inc., Pharming Healthcare, Inc., and Takeda California, Inc. JR is also a principal investigator for clinical trials sponsored by Ionis Pharmaceuticals and Kalvista Pharmaceuticals. MCG has received speaker bureau fees from BioCryst Pharmaceuticals, Inc., and Takeda. MOC reports receiving fees for serving as a consultant and a speaker for BioCryst Pharmaceuticals, Inc., CSL Behring, Kalvista Pharmaceuticals, and Pharming Technologies BV, and has received research funding from Takeda."

"Funding Development of this manuscript, and writing support were funded by BioCryst Pharmaceuticals, Inc."